Achieve Life Sciences Reports Wider-Than-Expected Q4 Loss on Development Costs
Achieve Life Sciences, Inc. posted a fourth-quarter loss of $0.28 per share, coming in line with the Wall Street’s expected loss of $0.28 per share. The late-stage pharmaceutical company, which focuses on developing cytisinicline for smoking cessation, reported a net loss of $14.7M for the quarter.
The Vancouver-based company has been advancing its lead asset through clinical trials across multiple markets. Cytisinicline, derived from a plant alkaloid, represents the company’s primary approach to helping smokers achieve nicotine independence. Achieve has been conducting development and commercialization activities spanning Canada, the United States, and the United Kingdom as it works to bring the treatment to market.
The quarterly results reflect ongoing investment in the company’s clinical programs and regulatory pathway. Achieve operates in the competitive smoking cessation market, where pharmaceutical interventions continue to address a significant public health challenge affecting millions of users across North America and Europe. The company’s share price trades on the Nasdaq under the ticker ACHV, where investor attention remains focused on clinical milestones and the path toward potential commercialization of its nicotine cessation therapy.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
The post Achieve Life Sciences, Inc. (ACHV) Reports Wider Q4 Loss Than Expected first appeared on Alphastreet.
